SCHEMBL18223993

SCHEMBL18223993

N#Cc1cncc(-c2ccc(C(F)(F)F)nc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 5/20 0.52
CYP11B1 P15538 4/20 0.52
MAP4K4 O95819 2/20 0.46
CYP1A2 P05177 1/20 0.43
METAP2 P50579 1/20 0.43
KCNH2 Q12809 2/20 0.41
BACE1 P56817 2/20 0.41
PIK3CA P42336 3/20 0.41
PI4KB Q9UBF8 2/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41
PI4KA P42356 1/20 0.41
PIK3CG P48736 1/20 0.41
TRPV4 Q9HBA0 1/20 0.40
LRRK2 Q5S007 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
MINK1 Q8N4C8 1/20 0.39
ABL1 P00519 1/20 0.38
PRMT5 O14744 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18223984 0.82 SYK (0.53) MAP4K4PIK3CAPI4KBPIK3CDPIK3CB
SCHEMBL16635169 0.81 MAP4K4 (0.47) MAP4K4KCNH2PIK3CAPI4KBPIK3CD
SCHEMBL16894199 0.80 KIF11 (0.62) CYP11B2CYP11B1MAP4K4CYP1A2METAP2
SCHEMBL21044112 0.76 PIK3CD (0.59) CYP11B2CYP11B1MAP4K4CYP1A2KCNH2
SCHEMBL18223772 0.76 GRM5 (0.48) LRRK2
SCHEMBL2983844 0.76 CYP11B2 (0.61) CYP11B2CYP11B1MAP4K4CYP1A2METAP2
SCHEMBL16894190 0.75 USP30 (0.42) MAP4K4KCNH2PIK3CAPI4KBPIK3CD
SCHEMBL29480819 0.75 TRPV4 (0.52) CYP11B2PIK3CATRPV4LRRK2
SCHEMBL17116617 0.75 CYP11B2 (0.62) CYP11B2CYP11B1MAP4K4PIK3CGPRMT5
SCHEMBL524167 0.75 TRPV4 (0.52) CYP11B2PIK3CATRPV4LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same EA PHARMA CO., LTD. (JP) 2020-04-21 US disclosed
EP-3101015-B1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO LTD (JP) 2019-09-18 EP disclosed
EP-3101015-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA Pharma Co., Ltd. (JP) 2016-12-07 EP disclosed
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME EA PHARMA CO., LTD. (JP) 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332999-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME TRPA1, TRPV1, TRPV2 CYP11B2 770/4885CYP11B1 1050/4885MAP4K4 1532/4885
US-10626112-B2 Heterocyclic sulfonamide derivative and medicine comprising same TRPA1, TRPV1, TRPV2 CYP11B2 770/4885CYP11B1 1050/4885MAP4K4 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.